The DOI matches its Crossref record; 46 of the 48 references it cites were found in a registry or an index.
Treatment with Flutamide, Metformin, and Their Combination Added to a Hypocaloric Diet in Overweight-Obese Women with Polycystic Ovary Syndrome: A Randomized, 12-Month, Placebo-Controlled Study
Abstract
CONTEXT: The few controlled trials performed so far indicate that the addition of metformin and/or flutamide to a hypocaloric diet in obese women with polycystic ovary syndrome (PCOS) effectively influences different phenotypic aspects of the syndrome. All these studies are, however, characterized by a short to medium period of treatment. OBJECTIVE: Our objective was to investigate the long-term effects of these therapies. DESIGN AND SETTING: We conducted a prospective, randomized, placebo-controlled trial at a medical center. PATIENTS: Of 80 overweight-obese women with PCOS, 76 completed the study. INTERVENTIONS: Patients were placed on a hypocaloric diet for the first month and then on a hypocaloric diet plus placebo, metformin (850 mg, orally, twice a day), flutamide (250 mg, orally, twice a day), or metformin plus flutamide for the subsequent 12 months (20 subjects in each group). MAIN OUTCOME MEASURES: We assessed clinical features, computerized tomography measurement of fat distribution, androgens, lipids, and fasting and glucose-stimulated glucose and insulin levels at baseline and after 6 and 12 months of treatment. RESULTS: After 6 months, compared with placebo, flutamide further decreased visceral/sc fat mass (P = 0.044), androstenedione (P < 0.001), dehydroepiandrosterone sulfate (P < 0.001), and hirsutism score (P < 0.001), whereas metformin further increased frequency of menstruation (P = 0.039). After 12 months, flutamide maintained the effects observed after 6 months on visceral/sc fat mass (P = 0.033) and androstenedione (P < 0.001), whereas it produced an additional decrease in dehydroepiandrosterone sulfate (P = 0.020) and hirsutism score (P = 0.019); metformin further improved the menstrual pattern (P = 0.013). Moreover, after 12 months, flutamide improved more than placebo the menstrual pattern (P = 0.008), glucose-stimulated glucose levels (P = 0.041), insulin sensitivity (P < 0.001), and low-density lipoprotein cholesterol levels (P = 0.003), whereas metformin decreased glucose-stimulated insulin levels (P = 0.014). The combination of the two drugs maintained the specific effect of each of the compounds, without any additive or synergistic effect. CONCLUSIONS: These findings add relevance to the usefulness of metformin and flutamide in the treatment of dieting overweight-obese PCOS women and provide a rationale for targeting different therapeutic options according to the required outcomes in the long term.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Duration of follow-up, except for two studies (Hoeger et al. , 2004; Gambineri et al. , 2006), was 6 months or shorter.”
From Metformin and lifestyle modification in polycystic ovary syndrome: systematic review and meta-analysis (2015) · cites this paper as Gambineri et al. , 2006
In the citing paper
“In addition, IGT was seen in three (15%) subjects on lifestyle + metformin and two (11%) on lifestyle + placebo at baseline which decreased to two (10%) and 0 respectively at 12 months.”
From Metformin and lifestyle modification in polycystic ovary syndrome: systematic review and meta-analysis (2015) · cites this paper as Gambineri et al. , 2006
In the citing paper
“In Gambineri et al. (2006), IFG was seen in three (15%) subjects on lifestyle + metformin and two (11%) on lifestyle + placebothat were unchanged at study end (12 months).”
From Metformin and lifestyle modification in polycystic ovary syndrome: systematic review and meta-analysis (2015) · cites this paper as Gambineri et al. , 2006
In the citing paper
“Data on BMI, testosterone, SHBG, FAI, menstruation, fasting glucose, glucose AUC and insulin AUC were also available from two studies with durations of 12 months and 48 weeks (Hoeger et al. , 2004; Gambineri et al. , 2006).”
From Metformin and lifestyle modification in polycystic ovary syndrome: systematic review and meta-analysis (2015) · cites this paper as Gambineri et al., 2006
In the citing paper
“Insulin resistance was assessed in five of nine studies comparing lifestyle + metformin with lifestyle + placebo (Pasquali et al. , 2000; Hoeger et al. , 2004; Gambineri et al. , 2006; Ladson et al. , 2011a, b).”
From Metformin and lifestyle modification in polycystic ovary syndrome: systematic review and meta-analysis (2015) · cites this paper as Gambineri et al. , 2006
In the citing paper
“IFG or IGT was assessed in five of nine studies comparing lifestyle + metformin with lifestyle + placebo (Hoeger et al. , 2004, 2008; Vanky et al. , 2004; Gambineri et al. , 2006; Otta et al. , 2010).”
From Metformin and lifestyle modification in polycystic ovary syndrome: systematic review and meta-analysis (2015) · cites this paper as Gambineri et al. , 2006
In the citing paper
“The number of menstrual cycles from 6 to 12 months was greater in the lifestyle + metformin compared with lifestyle + placebo groups (MD 1.38, 95% CI 0.47-2.29, P ¼ 0.003).”
From Metformin and lifestyle modification in polycystic ovary syndrome: systematic review and meta-analysis (2015) · cites this paper as Gambineri et al., 2006
In the citing paper
“There were two (10%) subjects with both IFG and IGT on lifestyle + metformin and one (5%) on lifestyle + placebo at baseline, which were all normal at 12 months (Gambineri et al. , 2006).”
From Metformin and lifestyle modification in polycystic ovary syndrome: systematic review and meta-analysis (2015) · cites this paper as Gambineri et al. , 2006
In the citing paper
“Body composition as assessed by computed tomography(CT)atL4-5wasprovided in two (Pasquali et al. , 2000; Gambineri et al. , 2006) of nine studies comparing lifestyle + metformin with lifestyle + placebo.”
From Metformin and lifestyle modification in polycystic ovary syndrome: systematic review and meta-analysis (2015) · cites this paper as Gambineri et al. , 2006
In the citing paper
“27 100.0%-92.49 [-164.14,-20.84]”
From Metformin and lifestyle modification in polycystic ovary syndrome: systematic review and meta-analysis (2015) · cites this paper as Gambineri et al., 2006
In the citing paper
“Gambineri and colleagues reported that metformin was better than placebo plus diet for menstrual pattern after 6 ( P =0.03) and 12 months ( P =0.003)”
From Assessment and management of polycystic ovary syndrome: Summary of an evidence-based guideline (2011) · cites this paper as [211]
Citations
Cites
Friedewald, W. T., Levy, R. I., & Fredrickson, D. S. (1972) · Clinical Chemistry · doi:10.1093/clinchem/18.6.499 · Cited by 32,423
Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C. (1985) · Diabetologia · doi:10.1007/bf00280883 · Cited by 31,502
(2004) · Fertility and Sterility · doi:10.1016/j.fertnstert.2003.10.004 · Cited by 9,050
The Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group (2004) · Human Reproduction · doi:10.1093/humrep/deh098 · Cited by 6,138
Matsuda, M., & DeFronzo, R. A. (1999) · Diabetes Care · doi:10.2337/diacare.22.9.1462 · Cited by 5,621
A short questionnaire for the measurement of habitual physical activity in epidemiological studies
Baecke, J. A. H., BUREMA, J., & Frijters, J. E. R. (1982) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/36.5.936 · Cited by 3,950
A Critical Evaluation of Simple Methods for the Estimation of Free Testosterone in Serum
Vermeulen, A., Verdonck, L., & Kaufman, J. M. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.10.6079 · Cited by 3,824
Clinical assessment of body hair growth in women.
Ferriman, D., & Gallwey, J. D. (1961) · Journal of Clinical Endocrinology and Metabolism · doi:10.1210/jcem-21-11-1440 · Cited by 2,556
BMPD statistical software manual
Dixon, W. (1988) · University of California Press eBooks · Cited by 2,536
Franks, S. (1995) · New England Journal of Medicine · doi:10.1056/nejm199509283331307 · Cited by 2,463
Research works printed but not linked: 1
- Norusis, 1990, Inc, SPSS/PC + 4.0 base and advanced statistics manuals., Chicago, SPSS
Cited by
Sorted by citations
Polycystic Ovary Syndrome: Definition, Aetiology, Diagnosis and Treatment
Escobar-Morreale, H. F. (2018) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2018.24 · Cited by 2,083
Fauser, B. C. J. M., Tarlatzis, B. C., Rebar, R. W., Legro, R. S., Balen, A. H., Lobo, R., Carmina, E., Chang, J., Yildiz, B. O., Laven, J. S. E., et al. (2012) · Fertility and Sterility · doi:10.1016/j.fertnstert.2011.09.024 · Cited by 1,976
Diamanti-Kandarakis, E., & Dunaif, A. (2012) · Endocrine Reviews · doi:10.1210/er.2011-1034 · Cited by 1,947
Dumesic, D. A., Oberfield, S. E., Stener-Victorin, E., Marshall, J. C., Laven, J. S., & Legro, R. S. (2015) · Endocrine Reviews · doi:10.1210/er.2015-1018 · Cited by 1,020
Joham, A. E., Norman, R. J., Stener-Victorin, E., Legro, R. S., Franks, S., Moran, L. J., Boyle, J., & Teede, H. J. (2022) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00163-2 · Cited by 838
The polycystic ovary syndrome: a position statement from the European Society of Endocrinology
Conway, G., Dewailly, D., Diamanti-Kandarakis, E., Escobar-Morreale, H. F., Franks, S., Gambineri, A., Kelestimur, F., Macut, D., Micic, D., Pasquali, R., et al. (2014) · European Journal of Endocrinology · doi:10.1530/eje-14-0253 · Cited by 676
Self-citationSanchez-Garrido, M. A., & Tena-Sempere, M. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2020.01.001 · Cited by 557
Escobar-Morreale, H. F., Carmina, E., Dewailly, D., Gambineri, A., Kelestimur, F., Moghetti, P., Pugeat, M., Qiao, J., Wijeyaratne, C. N., Witchel, S. F., et al. (2012) · Human Reproduction Update · doi:10.1093/humupd/dmr042 · Cited by 494
Self-citationObesity and the pubertal transition in girls and boys
Solorzano, C. M. B., & McCartney, C. R. (2010) · Reproduction · doi:10.1530/rep-10-0119 · Cited by 454
Palomba, S., Falbo, A., Zullo, F., & Orio, F. (2009) · Endocrine Reviews · doi:10.1210/er.2008-0030 · Cited by 426
LeBlanc, E. S., O’Connor, E., Whitlock, E. P., Patnode, C. D., & Kapka, T. J. (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-155-7-201110040-00006 · Cited by 409
Abdominal adiposity and the polycystic ovary syndrome
Escobar-Morreale, H. F., & Millán, J. L. S. (2007) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2007.07.003 · Cited by 386
Assessment and management of polycystic ovary syndrome: Summary of an evidence-based guideline
Teede, H. J., Misso, M. L., Deeks, A. A., Moran, L. J., Stuckey, B. G. A., Wong, J. L. A., Norman, R. J., Costello, M. F., & Groups, O. B. O. T. G. D. (2011) · Medical Journal of Australia · doi:10.5694/mja11.10915 · Cited by 379
Metabolic features of the reproductive phenotypes of polycystic ovary syndrome
Moran, L., & Teede, H. (2009) · Human Reproduction Update · doi:10.1093/humupd/dmp008 · Cited by 362
Naderpoor, N., Shorakae, S., de Courten, B., Misso, M. L., Moran, L. J., & Teede, H. J. (2015) · Human Reproduction Update · doi:10.1093/humupd/dmv025 · Cited by 334
Cardiometabolic Aspects of the Polycystic Ovary Syndrome
Randeva, H. S., Tan, B. K., Weickert, M. O., Lois, K. B., Nestler, J. E., Sattar, N. A., & Lehnert, H. (2012) · Endocrine Reviews · doi:10.1210/er.2012-1003 · Cited by 336
Obesity and diabetes: An update
Verma, S., & Hussain, M. E. (2016) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2016.06.017 · Cited by 343
Adolescent polycystic ovary syndrome according to the international evidence-based guideline
Peña, A. S., Witchel, S. F., Hoeger, K. M., Oberfield, S. E., Vogiatzi, M. G., Misso, M. L., Garad, R. M., Dabadghao, P., & Teede, H. J. (2020) · BMC Medicine · doi:10.1186/s12916-020-01516-x · Cited by 331
The role of androgens in metabolism, obesity, and diabetes in males and females
Navarro, G., Allard, C., Xu, W., & Mauvais‐Jarvis, F. (2015) · Obesity · doi:10.1002/oby.21033 · Cited by 289
Naderpoor, N., Shorakae, S., de Courten, B. V., Misso, M. L., Moran, L., & Teede, H. J. (2016) · Human Reproduction Update · doi:10.1093/humupd/dmv063 · Cited by 257
Diamanti‐Kandarakis, E., Christakou, C. D., Kandaraki, E., & Economou, F. (2009) · European Journal of Endocrinology · doi:10.1530/eje-09-0733 · Cited by 251
ACOG Practice Bulletin No. 194: polycystic ovary syndrome
(2018) · Obstetrics & Gynecology · doi:10.1097/aog.0000000000002656 · Cited by 231
Marsh, K. A., Steinbeck, K. S., Atkinson, F. S., Petocz, P., & Brand-Miller, J. C. (2010) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.2010.29261 · Cited by 228
Obesity and Endometrial Cancer
Shaw, E., Farris, M. S., McNeil, J., & Friedenreich, C. M. (2016) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-319-42542-9_7 · Cited by 208
The Diagnosis of Polycystic Ovary Syndrome in Adolescents
Rosenfield, R. L. (2015) · PEDIATRICS · doi:10.1542/peds.2015-1430 · Cited by 201
Review: Role of metformin in the management of polycystic ovary syndrome
Lashen, H. (2010) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018810380215 · Cited by 181
Swiglo, B. A., Cosma, M., Flynn, D. N., Kurtz, D. M., LaBella, M. L., Mullan, R. J., Erwin, P. J., & Montori, V. M. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-2430 · Cited by 166
Rachoń, D., & Teede, H. (2010) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2009.09.026 · Cited by 161
Agarwal, N., Rice, S., Bolusani, H., Luzio, S. D., Dunseath, G. J., Ludgate, M., & Rees, A. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-1985 · Cited by 162
Kite, C., Lahart, I. M., Afzal, I., Broom, D. R., Randeva, H., Kyrou, I., & Brown, J. E. (2019) · Systematic Reviews · doi:10.1186/s13643-019-0962-3 · Cited by 155
MECHANISMS IN ENDOCRINOLOGY: The sexually dimorphic role of androgens in human metabolic disease
Schiffer, L., Kempegowda, P., Arlt, W., & O’Reilly, M. (2017) · European Journal of Endocrinology · doi:10.1530/eje-17-0124 · Cited by 162
Childhood Obesity and Its Impact on the Development of Adolescent PCOS
Anderson, A., Solorzano, C. M. B., & McCartney, C. R. (2014) · Seminars in Reproductive Medicine · doi:10.1055/s-0034-1371092 · Cited by 149
Use of metformin in polycystic ovary syndrome
Mathur, R., Alexander, C. J., Yano, J., Trivax, B., & Azziz, R. (2008) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2008.09.010 · Cited by 150
Corbould, A. (2008) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.872 · Cited by 143
Transient prenatal androgen exposure produces metabolic syndrome in adult female rats
Demissie, M., Lazić, M., Foecking, E. M., Aird, F., Dunaif, A. E., & Levine, J. E. (2008) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.90208.2008 · Cited by 143
Feng, W., Bi, Y., Li, P., Yin, T., Gao, C., Shen, S., Gao, L., Yang, D., & Zhu, D. (2018) · Journal of Diabetes Investigation · doi:10.1111/jdi.12888 · Cited by 149
Cosma, M., Swiglo, B. A., Flynn, D. N., Kurtz, D. M., LaBella, M. L., Mullan, R. J., Elamin, M. B., Erwin, P. J., & Montori, V. M. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-2429 · Cited by 129
Drug Insight: insulin-sensitizing drugs in the treatment of polycystic ovary syndrome—a reappraisal
Dunaif, A. E. (2008) · Nature Clinical Practice Endocrinology & Metabolism · doi:10.1038/ncpendmet0787 · Cited by 122
The effects of old, new and emerging medicines on metabolic aberrations in PCOS
Bargiota, Α., & Diamanti‐Kandarakis, E. (2012) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018812437355 · Cited by 120
Anderson, H., Fogel, N. R., Grebe, S. K. G., Singh, R. J., Taylor, R. L., & Dunaif, A. E. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2651 · Cited by 118
Jensterle, M., Kravos, N. A., Pfeifer, M., Kocjan, T., & Janez, A. (2015) · Hormones · doi:10.1007/bf03401383 · Cited by 117
Domecq, J. P., Prutsky, G., Mullan, R. J., Sundaresh, V., Wang, A. T., Erwin, P. J., Welt, C., Ehrmann, D., Montori, V. M., & Murad, M. H. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-2374 · Cited by 115
Zeng, L., Rana, S., Hussain, L., Asif, M., Mehmood, M. H., Imran, I., Younas, A., Mahdy, A., Al‐Joufi, F. A., & Abed, S. N. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.874914 · Cited by 138
Androgens and ovarian function: translation from basic discovery research to clinical impact
Walters, K. A., Rodriguez Paris, V, Aflatounian, A., & Handelsman, D. J. (2019) · Journal of Endocrinology · doi:10.1530/joe-19-0096 · Cited by 104
Ganie, M. A., Khurana, M. L., Nisar, S., Shah, P. A., Shah, Z. A., Kulshreshtha, B., Gupta, N., Zargar, M. A., Wani, T. A., Mudasir, S., et al. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-1040 · Cited by 109
Neuroendocrine Impairments of Polycystic Ovary Syndrome
Ruddenklau, A., & Campbell, R. E. (2019) · Endocrinology · doi:10.1210/en.2019-00428 · Cited by 116
Adipose tissue expandability and the early origins of PCOS
de Zegher, F., López‐Bermejo, A., & Ibáñez, L. (2009) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2009.06.003 · Cited by 108
Guan, Y., Wang, D., Bu, H., Zhao, T., & Wang, H. (2020) · International Journal of Endocrinology · doi:10.1155/2020/5150684 · Cited by 109
A Novel Approach for Polycystic Ovary Syndrome Prediction Using Machine Learning in Bioinformatics
Nasim, S., Almutairi, M. S., Munir, K., Raza, A., & Younas, F. (2022) · IEEE Access · doi:10.1109/access.2022.3205587 · Cited by 105
Escobar-Morreale, H. F., Alvarez-Blasco, F., Botella-Carretero, J. I., & Luque‐Ramírez, M. (2014) · Human Reproduction · doi:10.1093/humrep/deu198 · Cited by 105
Acupuncture in Polycystic Ovary Syndrome: Current Experimental and Clinical Evidence
Stener‐Victorin, E., Jedel, E., & Mannerås, L. (2007) · Journal of Neuroendocrinology · doi:10.1111/j.1365-2826.2007.01634.x · Cited by 100
Dermatologic Manifestations of Polycystic Ovary Syndrome
Lee, A. T., & Zane, L. T. (2007) · American Journal of Clinical Dermatology · doi:10.2165/00128071-200708040-00003 · Cited by 98
Wang, F., Wu, Y. T., Zhu, Y. ‐., Ding, T., Batterham, R. L., Qu, F., & Hardiman, P. (2018) · Obesity Reviews · doi:10.1111/obr.12720 · Cited by 96
Christakou, C. D., & Diamanti‐Kandarakis, E. (2008) · Women s Health · doi:10.2217/17455057.4.6.583 · Cited by 91
Diet and nutrition in polycystic ovary syndrome (PCOS): Pointers for nutritional management
Farshchi, H., Rane, A., Love, A., & Kennedy, R. L. (2007) · Journal of Obstetrics and Gynaecology · doi:10.1080/01443610701667338 · Cited by 87
Effect of weight loss on menstrual function in adolescents with polycystic ovary syndrome
Ornstein, R. M., Copperman, N. M., & Jacobson, M. S. (2011) · Journal of Pediatric and Adolescent Gynecology · doi:10.1016/j.jpag.2011.01.002 · Cited by 82
Sex hormones, obesity and type 2 diabetes: is there a link?
Gambineri, A., & Pelusi, C. (2018) · Endocrine Connections · doi:10.1530/ec-18-0450 · Cited by 82
Self-citationRyan, G. E., Malik, S., & Mellon, P. L. (2018) · Endocrinology · doi:10.1210/en.2017-03218 · Cited by 83
A systematic review of commonly used medical treatments for hirsutism in women
Koulouri, O., & Conway, G. S. (2007) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2007.03105.x · Cited by 80
Marzouk, T. M., & Sayed Ahmed, W. A. (2015) · Journal of Pediatric and Adolescent Gynecology · doi:10.1016/j.jpag.2015.01.002 · Cited by 73
Sex-dependent role of glucocorticoids and androgens in the pathophysiology of human obesity
Pasquali, R., Vicennati, V, Gambineri, A., & Pagotto, U. (2008) · International Journal of Obesity · doi:10.1038/ijo.2008.129 · Cited by 74
Self-citationCoviello, A. D., Sam, S., Legro, R. S., & Dunaif, A. E. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-1333 · Cited by 77
Alesi, S., Forslund, M., Melin, J. M., Romualdi, D., Peña, A. S., Tay, C. T., Witchel, S. F., Teede, H. J., & Mousa, A. (2023) · EClinicalMedicine · doi:10.1016/j.eclinm.2023.102162 · Cited by 73
Melin, J., Forslund, M., Alesi, S., Piltonen, T., Romualdi, D., Spritzer, P. M., Tay, C. T., Pena, A., Witchel, S. F., Mousa, A., et al. (2023) · European Journal of Endocrinology · doi:10.1093/ejendo/lvad098 · Cited by 72
A review on critical appraisal and pathogenesis of polycystic ovarian syndrome
Hajam, Y. A., Rather, H., Neelam, N., Kumar, R., Basheer, M., & Reshi, M. S. (2024) · Endocrine and Metabolic Science · doi:10.1016/j.endmts.2024.100162 · Cited by 86
Puberty and its disorders in the female
Rosenfield, R. L., Cooke, D. W., & Radovick, S. (2014) · Elsevier eBooks · doi:10.1016/b978-1-4557-4858-7.00024-x · Cited by 67
Tomlinson, J., Millward, A., Stenhouse, E., & Pinkney, J. (2010) · Diabetic Medicine · doi:10.1111/j.1464-5491.2010.02994.x · Cited by 66
Interventions for hirsutism (excluding laser and photoepilation therapy alone)
van Zuuren, E. J., Fedorowicz, Z., Carter, B., & Pandis, N. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010334.pub2 · Cited by 65
Ovulatory effects of flutamide in the polycystic ovary syndrome
Paradisi, R., Fabbri, R., Battaglia, C., & Venturoli, S. (2013) · Gynecological Endocrinology · doi:10.3109/09513590.2012.754876 · Cited by 65
Comparative Analysis of Machine Learning Algorithms in Diagnosis of Polycystic Ovarian Syndrome
Hassan, M. M., & Mirza, T. (2020) · International Journal of Computer Applications · doi:10.5120/ijca2020920688 · Cited by 65
Cardio-Metabolic Disease and Polycystic Ovarian Syndrome (PCOS): A Narrative Review
Sangaraju, S. L., Yepez, D., Grandes, X. A., Manjunatha, R. T., & Habib, S. (2022) · Cureus · doi:10.7759/cureus.25076 · Cited by 77
Saadati, S., Mason, T., Godini, R., Vanky, E., Teede, H. J., & Mousa, A. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16422 · Cited by 89
Azarchi, S., Bienenfeld, A., Sicco, K. L., Marchbein, S., Shapiro, J., & Nagler, A. R. (2018) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2018.08.061 · Cited by 64
Luque-Ramírez, M., Nattero-Chávez, L., Ortiz Flores, A. E., & Escobar-Morreale, H. F. (2018) · Human Reproduction Update · doi:10.1093/humupd/dmx039 · Cited by 62
Androgen signaling pathways driving reproductive and metabolic phenotypes in a PCOS mouse model
Aflatounian, A., Edwards, M. C., Paris, V. R., Bertoldo, M. J., Desai, R., Gilchrist, R. B., Ledger, W. J., Handelsman, D. J., & Walters, K. A. (2020) · Journal of Endocrinology · doi:10.1530/joe-19-0530 · Cited by 61
Anti-androgen hormonal therapy for cancer and other diseases
Student, S., Hejmo, T., Poterała-Hejmo, A., Leśniak, A., & Bułdak, R. J. (2019) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2019.172783 · Cited by 63
Evidence-based approach to cutaneous hyperandrogenism in women
Schmidt, T. H., & Shinkai, K. (2015) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2015.05.026 · Cited by 60
Gambineri, A., Semple, R. K., Forlani, G., Genghini, S., Grassi, I., Hyden, C. S. S., Pagotto, U., O’Rahilly, S., & Pasquali, R. (2008) · European Journal of Endocrinology · doi:10.1530/eje-08-0272 · Cited by 60
Self-citationShi, D., Dyck, M. K., Uwiera, R. R. E., Russell, J. C., Proctor, S. D., & Vine, D. F. (2009) · Endocrinology · doi:10.1210/en.2008-1612 · Cited by 58
JENSTERLE, M., GORICAR, K., & JANEZ, A. (2016) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2016.3081 · Cited by 56
McGee, W., Bishop, C., Pohl, C., Chang, R., Marshall, J., Pau, F., Stouffer, R., & Cameron, J. (2014) · American Journal of Physiology. Endocrinology and Metabolism · doi:10.1152/ajpendo.00310.2013 · Cited by 50
Polycystic Ovary Syndrome: A Common Endocrine Disorder and Risk Factor for Vascular Disease
McGowan, M. P. (2011) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-011-0130-0 · Cited by 59
Combined Low-Dose Pioglitazone, Flutamide, and Metformin for Women with Androgen Excess
Ibáñez, L., López‐Bermejo, A., del Río, L., Enríquez, G., Valls, C., & de Zegher, F. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-2684 · Cited by 51
Androgens in Polycystic Ovary Syndrome: The Role of Exercise and Diet
Giallauria, F., Palomba, S., Vigorito, C., Tafuri, M. G., Colao, A., Lombardi, G., & Orio, F. (2009) · Seminars in Reproductive Medicine · doi:10.1055/s-0029-1225258 · Cited by 52
Metabolic Syndrome in Polycystic Ovary Syndrome
Pasquali, R. (2018) · Frontiers of hormone research · doi:10.1159/000485995 · Cited by 49
Self-citationTHERAPY OF ENDOCRINE DISEASE: Treatment of hirsutism in the polycystic ovary syndrome
Pasquali, R., & Gambineri, A. (2014) · European Journal of Endocrinology · doi:10.1530/eje-13-0585 · Cited by 49
Self-citationLi, X., Pishdari, B., Cui, P., Hu, M., Yang, H.-P., Guo, Y.-R., Jiang, H., Feng, Y., Billig, H., & Shao, R. (2015) · International Journal of Biological Sciences · doi:10.7150/ijbs.13109 · Cited by 48
Pasquali, R., Patton, L., Pocognoli, P., Cognigni, G. E., & Gambineri, A. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-0870 · Cited by 47
Self-citationContemporary approaches to the management of polycystic ovary syndrome
Pasquali, R. (2018) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018818756790 · Cited by 49
Self-citationSarkar, M. A., Suzuki, A., Abdelmalek, M. F., Yates, K. P., Wilson, L., Bass, N. M., Gill, R. M., Cedars, M. I., & Terrault, N. A. (2020) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2020.09.045 · Cited by 46
Antiandrogenic Contraceptives Increase Serum Adiponectin in Obese Polycystic Ovary Syndrome Patients
Luque‐Ramírez, M., Álvarez‐Blasco, F., & Escobar-Morreale, H. F. (2008) · Obesity · doi:10.1038/oby.2008.491 · Cited by 46
Benrick, A., Maliqueo, M. A., Sun, M., Villanueva, J. A., Feng, Y., Ohlsson, C., Dulęba, A. J., & Stener‐Victorin, E. (2013) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2013/964070 · Cited by 45
Puberty and Its Disorders in the Female
Rosenfield, R. L., Cooke, D. W., & Radovick, S. (2008) · Elsevier eBooks · doi:10.1016/b978-141604090-3.50019-3 · Cited by 44
Liu, Q., Long, Q., Zhao, J., Wu, W., Lin, Z., Sun, W., Gu, P., Deng, T., Loomes, K. M., Wu, D., et al. (2023) · Research · doi:10.34133/research.0182 · Cited by 42
Polycystic ovary syndrome: chemical pharmacotherapy
Rocca, M. L., Venturella, R., Mocciaro, R., Cello, A. D., Sacchinelli, A., Russo, V. M., Trapasso, S., Zullo, F., & Morelli, M. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.1047344 · Cited by 41
What every physician should know about polycystic ovary syndrome
Rosenfield, R. L. (2008) · Dermatologic Therapy · doi:10.1111/j.1529-8019.2008.00217.x · Cited by 42
SMOTE-Based Automated PCOS Prediction Using Lightweight Deep Learning Models
Ahmad, R., Maghrabi, L. A., Khaja, I. A., Maghrabi, L. A., & Ahmad, M. (2024) · Diagnostics · doi:10.3390/diagnostics14192225 · Cited by 38
Cardiometabolic abnormalities in the polycystic ovary syndrome: Pharmacotherapeutic insights
Westerveld, H. E., Hoogendoorn, M., de Jong, A. W. F., Goverde, A. J., Fauser, B. C. J. M., & Dallinga‐Thie, G. M. (2008) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2008.04.009 · Cited by 38
Alpañés, M., Álvarez‐Blasco, F., Fernández‐Durán, E., Luque‐Ramírez, M., & Escobar-Morreale, H. F. (2017) · European Journal of Endocrinology · doi:10.1530/eje-17-0516 · Cited by 37
Gibb, F. W., Dixon, J. M., Clarke, C., Homer, N. Z. M., Faqehi, A. M. M., Andrew, R., & Walker, B. R. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-02339 · Cited by 36
Metadata
- Authors
- Gambineri, A., Patton, L., Vaccina, A., Cacciari, M., Morselli-Labate, A. M., Cavazza, C., Pagotto, U., & Pasquali, R.
- Affiliations
- IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola (IT)
- Division of Endocrinology, Department of Internal Medicine, and Center for Applied Biomedical Research, S. Orsola-Malpighi Hospital, University of Bologna, 40138 Bologna, Italy
- Corresponding author
- Pasquali, Renato
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2006-10-01
- Volume
- 91
- Issue
- 10
- Pages
- 3970-3980
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2014108789
- Cited by
- 221
- References
- 48
- Citations by year
- 2026: 4 · 2025: 14 · 2024: 3 · 2023: 8 · 2022: 11 · 2021: 11 · 2020: 12 · 2019: 7 · 2018: 14 · 2017: 10 · 2016: 7 · 2015: 20 · 2014: 12 · 2013: 10 · 2012: 9
- FWCI
- 17.46
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic and Kidney Cyst Diseases
- Keywords
- polycystic ovary syndrome, flutamide, metformin, hypocaloric diet, obesity, overweight women, long-term treatment outcomes, visceral fat, androgen levels, hirsutism, menstrual pattern, insulin sensitivity, glucose-stimulated insulin secretion, lipid profile, body fat distribution, combination therapy, weight loss, insulin resistance, androgen receptor antagonists
- MeSH terms
- Adipose Tissue, Adult, Energy Intake, Diet, Reducing, Drug Therapy, Combination, Female, Flutamide, Humans, Insulin Resistance, Metformin, Obesity, Polycystic Ovary Syndrome, Prospective Studies, Sex Hormone-Binding Globulin, Gonadal Steroid Hormones
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
